Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

91 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Circulating tumor cells: a multifunctional biomarker.
Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Yap TA, et al. Among authors: lorente d. Clin Cancer Res. 2014 May 15;20(10):2553-68. doi: 10.1158/1078-0432.CCR-13-2664. Clin Cancer Res. 2014. PMID: 24831278 Review.
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G. Omlin A, et al. Among authors: lorente d. Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8. Br J Cancer. 2013. PMID: 23928659 Free PMC article.
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC. Bianchini D, et al. Among authors: lorente d. Br J Cancer. 2013 Nov 12;109(10):2579-86. doi: 10.1038/bjc.2013.619. Epub 2013 Oct 29. Br J Cancer. 2013. PMID: 24169353 Free PMC article. Clinical Trial.
Visceral disease in castration-resistant prostate cancer.
Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, de Bono J, Attard G. Pezaro C, et al. Among authors: lorente d. Eur Urol. 2014 Feb;65(2):270-273. doi: 10.1016/j.eururo.2013.10.055. Epub 2013 Nov 22. Eur Urol. 2014. PMID: 24295792 Free PMC article.
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.
Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G. Omlin A, et al. Among authors: lorente d. Br J Cancer. 2014 Jan 7;110(1):267-8. doi: 10.1038/bjc.2013.737. Epub 2013 Dec 3. Br J Cancer. 2014. PMID: 24300975 Free PMC article. No abstract available.
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
Ravi P, Mateo J, Lorente D, Zafeiriou Z, Altavilla A, Ferraldeschi R, Sideris S, Grist E, Smith A, Wong S, Bianchini D, Attard G, de Bono JS. Ravi P, et al. Among authors: lorente d. Eur Urol. 2014 Jul;66(1):8-11. doi: 10.1016/j.eururo.2014.03.020. Epub 2014 Mar 26. Eur Urol. 2014. PMID: 24685433 Clinical Trial.
Tumor clone dynamics in lethal prostate cancer.
Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G. Carreira S, et al. Among authors: lorente d. Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448. Sci Transl Med. 2014. PMID: 25232177 Free PMC article.
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G. Lorente D, et al. Br J Cancer. 2014 Dec 9;111(12):2248-53. doi: 10.1038/bjc.2014.531. Epub 2014 Oct 14. Br J Cancer. 2014. PMID: 25314055 Free PMC article.
91 results